#United States #Durham #epigenetics #EpiCypher #Chromatin

Driving Innovation in Epigenetics: EpiCypher's 2024 Impact in Chromatin Research

EpiCypher celebrated a pivotal year in 2024, establishing a benchmark in chromatin research with an impressive portfolio of seven peer-reviewed publications and an astounding over 550 product citations. This remarkable achievement underscores EpiCypher’s relentless pursuit of advancing the field of genomics, specifically in epigenetics, through their innovative array of chromatin technologies, assays, and services.

Dr. Michael-Christopher Keogh, the Chief Scientific Officer at EpiCypher, expressed pride in the incredible research generated through their CUTANA™ assays, referencing both the CUTRUN and CUTTag technologies. He noted, "EpiCypher R&D has shown remarkable productivity this year, and we anticipate collaborating with our partners on new groundbreaking applications as we move into 2025."

Manuscript Contributions

In 2024, EpiCypher scientists significantly contributed to the epigenetics field by collaborating on 16 manuscripts, showcasing innovative research themes and technological advancements. Among these contributions are:

1. Reader CUTRUN Technology: Facilitating the profiling of co-occurring epigenomic features alongside researchers like Catherine Musselman, published in eLife (10.7554/eLife.78866).
2. Nucleosome Structure Insights: A collaborative work with Chao Lu and Karim-Jean Armache in Science Advances, highlighting nucleosome structures critical for chromatin interactions related to diseases (10.1126/sciadv.adp0975).
3. Immunotherapy Resistance Pathways: Discovery of chromatin remodeling pathways that contribute to immunotherapy resistance, with Alberto Ciccia in Cell (10.1016/j.cell.2024.01.008).
4. Histone Ubiquitination Screening: High-throughput technologies to analyze histone ubiquitination PTMs, a collaboration with Cynthia Wolberger published in Nucleic Acids Research (10.1093/nar/gkae698).
5. Historical Context of Chromatin Research: Reflecting on David Allis’s contributions and the nucleosome structure’s relative significance in the field (10.1042/BCJ20230342).
6. EpiCypher-Validated CUTRUN Protocol: An updated protocol showcasing streamlined sample preparation and quality control (10.1101/2024.12.03.626419).

Global Product Reach

EpiCypher’s products found extensive usage worldwide, manifesting in over 550 product citations from regions including the US, Canada, Europe, and Australia. The application of CUTANA CUTRUN and CUTTag chromatin mapping kits, enzymes, antibodies, and other reagents was prevalent across numerous significant studies. Key applications included:

• - Characterizing novel drug targets identified through CRISPR screenings, as showcased by recent publications in Nature Biotechnology and Cell Reports.
• - Advancing techniques for T cell immunotherapies, highlighted by research in Cancer Cell.
• - Examining oncohistone proteins and their influence on gene expression in studies published in Molecular Cell.
• - Exploring chromatin structures in atypical organisms, contributing to diverse studies including those on nonhuman primates and viruses.

Looking Forward to 2025

As EpiCypher gears up for 2025, the company is committed to expanding access to top-tier chromatin and epigenomics technologies across academia, biotech, and the pharmaceutical sectors. Moving forward, EpiCypher will launch new sequencing technologies aimed at DNA methylation and multiomics, while also broadening research applications.

Dr. Martis Cowles, Chief Business Officer, summarized the ambitious outlook, stating, "2024 was momentous for EpiCypher, and we aim to maintain this momentum. With the rise in adoption of our CUTRUN and CUTTag technologies, paired with our focus on breakthrough solutions in epigenomics, we anticipate another exhilarating year ahead."

For those interested in learning more about EpiCypher’s scientific contributions and innovations, the company encourages exploring their interactive database and following their updates on platforms such as LinkedIn, X, and Bluesky for ongoing developments in epigenetics.

About EpiCypher

Founded to address the surging demand for high-quality reagents to study chromatin regulation, EpiCypher stands at the forefront of chromatin mapping technologies. Their flagship CUTANA® platform specializes in advanced profiling assays, delivering a wide array of research tools designed to drive epigenetics-focused drug discovery. EpiCypher remains dedicated to promoting these transformative technologies, providing researchers globally with superior products and services for groundbreaking studies.